53 employees
Oxurion is a biotech drug development company focused on developing therapies for retinal disorders, now focusing on diabetic eye diseases.
1991
$12M
from 2 investors over 2 rounds
ThromboGenics NV raised $3M on March 2, 2023
Investors: -
ThromboGenics NV raised $12M on March 3, 2022
Investors: Epacria Capital Partners